START and STAY with linagliptin*
The only approved DPP4i that does not require dose reduction based on kidney function†1-7.


Required DPP4i dose with declining kidney function

TRAJENTA® START and STAY with linagliptin. The only approved DPP4i that does not require dose reduction based on kidney function

*The maximum recommended daily dose of JENTADUETO® contains 5 mg of linagliptin plus 2,000 mg of metformin hydrochloride.
JENTADUETO® must not be used in patients with GFR <45 mL/min due to the active substance metformin. Linagliptin may be continued as a single entity tablet (TRAJENTA®) at the same total daily dose of 5 mg if metformin is discontinued due to evidence of kidney impairment.

BID: Twice daily; CKD: Chronic kidney disease; GFR: Glomerular filtration rate; SPC: Single-pill combination; QD: Once daily.

See DPP4i dosing chart for linagliptin monotherapy